| DB ID | MyCo_1411 |
| Title | Differential genes expression analysis of invasive aspergillosis: a bioinformatics study based on mRNA/microRNA |
| Year | 2020 |
| PMID | 33344664 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Ethics Committee of the School of Medicine, Tarbiat Modares University, Tehran, Iran. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | None |
| Sample source | None |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | S100B |
| Biomarker Full Name | (Calcium-binding protein B)S100B |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | Iran |
| Cohort | In the present study, the gene expression dataset GSE78000 with the platform of Affymetrix Human Genome 19 (GPL21464) was extracted from the gene expression omnibus (GEO) database (https://www.ncbi.nlm. nih.gov/gds). GSE78000 included 23 samples obtained from haematological patients with IA and 13 samples from non-IA haematological patients. Two of the non-IA samples were reported as a possible invasive fungal disease (IFD). Nine control samples from healthy donors were also included in the dataset. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.9565 |
| Specificity | 0.6923 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) exhibits more than 80 percent mortality rate in individuals with immunodeficiency, including patients with blood malignancies and bone marrow transplant recipients. The incidence of IA has not been well elucidated yet, however it was considered responsible for 30-50 percent of invasive fungal diseases among immunocompromised patients. Aspergillus fumigatus and Aspergillus flavus are the most common cause of IA. The diagnosis is mainly based on clinical examinations and serological tests. The gold standard methods are histopathological tests and tissue culture following the lung biopsy or bronchoalveolar lavage (BAL). However, this invasive approach is contraindicated in severe conditions such as thrombocytopenia. Since IA progresses rapidly, the high mortality rate is a great challenge due to the lack of prompt standard diagnostic test. |
| Technique | Bioinformatics analysis |
| Analysis Method | Computational Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Computational Analysis |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
